Cargando…

Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside

Motor neurons (MN) degeneration is a main feature of amyotrophic lateral sclerosis (ALS), a neurological disorder with a progressive course. The diagnosis of ALS is essentially a clinical one. Most common symptoms include a gradual neurological deterioration that reflect the impairment and subsequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Forostyak, Serhiy, Sykova, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660803/
https://www.ncbi.nlm.nih.gov/pubmed/29114200
http://dx.doi.org/10.3389/fnins.2017.00591
_version_ 1783274360919818240
author Forostyak, Serhiy
Sykova, Eva
author_facet Forostyak, Serhiy
Sykova, Eva
author_sort Forostyak, Serhiy
collection PubMed
description Motor neurons (MN) degeneration is a main feature of amyotrophic lateral sclerosis (ALS), a neurological disorder with a progressive course. The diagnosis of ALS is essentially a clinical one. Most common symptoms include a gradual neurological deterioration that reflect the impairment and subsequent loss of muscle functions. Up-to-date ALS has no therapy that would prevent or cure a disease. Modern therapeutic strategies comprise of neuroprotective treatment focused on antiglutamatergic, antioxidant, antiapoptotic, and anti-inflammatory molecules. Stem cells application and gene therapy has provided researchers with a powerful tool for discovery of new mechanisms and therapeutic agents, as well as opened new perspectives for patients and family members. Here, we review latest progress made in basic, translational and clinical stem cell research related to the ALS. We overviewed results of preclinical and clinical studies employing cell-based therapy to treat neurodegenerative disorders. A special focus has been made on the neuroprotective properties of adult mesenchymal stromal cells (MSC) application into ALS patients. Finally, we overviewed latest progress in the field of embryonic and induced pluripotent stem cells used for the modeling and application during neurodegeneration in general and in ALS in particular.
format Online
Article
Text
id pubmed-5660803
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56608032017-11-07 Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside Forostyak, Serhiy Sykova, Eva Front Neurosci Neuroscience Motor neurons (MN) degeneration is a main feature of amyotrophic lateral sclerosis (ALS), a neurological disorder with a progressive course. The diagnosis of ALS is essentially a clinical one. Most common symptoms include a gradual neurological deterioration that reflect the impairment and subsequent loss of muscle functions. Up-to-date ALS has no therapy that would prevent or cure a disease. Modern therapeutic strategies comprise of neuroprotective treatment focused on antiglutamatergic, antioxidant, antiapoptotic, and anti-inflammatory molecules. Stem cells application and gene therapy has provided researchers with a powerful tool for discovery of new mechanisms and therapeutic agents, as well as opened new perspectives for patients and family members. Here, we review latest progress made in basic, translational and clinical stem cell research related to the ALS. We overviewed results of preclinical and clinical studies employing cell-based therapy to treat neurodegenerative disorders. A special focus has been made on the neuroprotective properties of adult mesenchymal stromal cells (MSC) application into ALS patients. Finally, we overviewed latest progress in the field of embryonic and induced pluripotent stem cells used for the modeling and application during neurodegeneration in general and in ALS in particular. Frontiers Media S.A. 2017-10-24 /pmc/articles/PMC5660803/ /pubmed/29114200 http://dx.doi.org/10.3389/fnins.2017.00591 Text en Copyright © 2017 Forostyak and Sykova. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Forostyak, Serhiy
Sykova, Eva
Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
title Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
title_full Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
title_fullStr Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
title_full_unstemmed Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
title_short Neuroprotective Potential of Cell-Based Therapies in ALS: From Bench to Bedside
title_sort neuroprotective potential of cell-based therapies in als: from bench to bedside
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660803/
https://www.ncbi.nlm.nih.gov/pubmed/29114200
http://dx.doi.org/10.3389/fnins.2017.00591
work_keys_str_mv AT forostyakserhiy neuroprotectivepotentialofcellbasedtherapiesinalsfrombenchtobedside
AT sykovaeva neuroprotectivepotentialofcellbasedtherapiesinalsfrombenchtobedside